Financial Performance - The company reported a revenue of RMB 6,294.59 million for the year ending December 31, 2023, representing an increase of 68.08% compared to RMB 3,744.95 million for the previous year[2]. - EBITDA for the same period was RMB 2,745.44 million, reflecting a significant increase of 293.09% from RMB 698.35 million in the prior year[2]. - Net profit attributable to equity holders was RMB 1,992.62 million, a remarkable increase of 2,501.23% from RMB 76.60 million in the previous year[2]. - Basic and diluted earnings per share for the year were RMB 2.26, compared to RMB 0.09 in the previous year[4]. - The gross profit for the year was RMB 4,985.76 million, up from RMB 2,846.07 million, indicating a strong growth in profitability[5]. - Operating profit for the year was RMB 2,354.20 million, a significant increase from RMB 321.07 million in the previous year[5]. - The pre-tax profit for the year was RMB 2,126,771,000, a substantial increase compared to RMB 39,422,000 in the previous year[22]. - The total tax expense for the year was RMB 270,945,000, compared to a tax benefit of RMB (9,817,000) in the previous year[20]. - The company reported a net profit of RMB 1,992,624 thousand for the year 2023, a substantial increase from RMB 76,603 thousand in 2022, representing a growth of over 2,500%[9]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 8,412.11 million, compared to RMB 6,949.02 million in the previous year[7]. - Cash and cash equivalents increased to RMB 1,674.41 million from RMB 923.54 million, indicating improved liquidity[7]. - Trade and other receivables rose to RMB 2,112.80 million from RMB 1,036.92 million, reflecting growth in sales and collections[7]. - The company's total liabilities decreased from RMB 879,018 thousand in 2022 to RMB 476,596 thousand in 2023, indicating a reduction of about 45.7%[8]. - The company's total liabilities increased to RMB 3,760,090,000 as of December 31, 2023, from RMB 3,670,087,000 in 2022, reflecting a growth of approximately 2.4%[31]. - The company's trade receivables amounted to RMB 2,000,557 thousand, an increase from RMB 892,611 thousand in the previous year, reflecting a significant growth[39]. - The total value of bank loans increased to RMB 2,607,804 thousand in 2023 from RMB 914,872 thousand in 2022, indicating a substantial rise in borrowing[43]. Equity and Retained Earnings - As of December 31, 2023, the company's net assets increased to RMB 7,935,513 thousand, up from RMB 6,070,001 thousand in 2022, representing a growth of approximately 30.7%[8]. - The company's retained earnings rose significantly to RMB 3,947,144 thousand in 2023 from RMB 2,065,811 thousand in 2022, marking an increase of about 91%[9]. - Total equity attributable to shareholders reached RMB 7,935,513 thousand in 2023, compared to RMB 5,884,884 thousand in 2022, reflecting a growth of approximately 34.8%[9]. Research and Development - The group’s research and development expenses were impacted by tax effects related to machinery and equipment purchases, amounting to RMB (26,709,000) in tax effects[22]. - The group’s research and development investment in 焦谷氨酸荣格列净 reached RMB 197.11 million, accounting for 3.13% of operating income[60]. - The group’s research and development in the endocrine and metabolic disease sector has shown exceptional progress, with a complete product line planning for insulin products[58]. Product and Market Development - The company operates primarily in the pharmaceutical production and sales sector, with no geographical segment reporting due to the nature of its business[12]. - The company plans to expand its product line for anti-infective drugs in response to market demand[51]. - The company aims to enhance the development of chronic disease medications, focusing on safe and effective treatment options[51]. - The company has achieved significant progress in internationalizing its innovative drug industry, with several products successfully entering international markets[50]. - The group aims to establish its brand "可威" as the leading antiviral medication through extensive academic promotion and brand building efforts, enhancing brand recognition among patients and healthcare providers[54]. Employee and Workforce - The total employee cost for the year ended December 31, 2023, was approximately RMB 714.30 million, with a total workforce of 4,618 employees[85]. - The employee distribution by age shows that 68.80% are between 31 and 50 years old, while 28.93% are 30 years old or younger[86]. - The group adheres to labor laws and provides various employee benefits, including social insurance and housing funds, with plans to enhance employee welfare in the future[88]. Corporate Governance and Compliance - The board of directors includes executive directors and independent non-executive directors, indicating a diverse governance structure[120]. - The audit committee has reviewed the annual performance announcement and the financial statements prepared in accordance with international financial reporting standards[97]. Dividends and Shareholder Returns - The company did not recommend the payment of a final dividend for the year ending December 31, 2023, consistent with the previous year[2]. - The company has no declared or paid dividends for the years ending December 31, 2022, and December 31, 2023[46]. Agreements and Contracts - The company entered into a leasing and service framework agreement with Shenzhen Dongyangguang Industrial Development Co., Ltd., with proposed annual limits of RMB 12,383,300, RMB 12,999,500, and RMB 13,003,300 for three consecutive years[100]. - The company established a raw material and pharmaceutical sales framework agreement with Shenzhen Dongyangguang Industrial Development Co., Ltd., with proposed annual limits of RMB 18,000,000, RMB 20,000,000, and RMB 22,000,000 for three consecutive years[100].
东阳光长江药业(01558) - 2023 - 年度业绩